Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A biosimilar - Revance Therapeutics/Viatris Inc

Next Previous
Search
Drug Profile

Botulinum toxin A biosimilar - Revance Therapeutics/Viatris Inc

Alternative Names: DaxibotulinumtoxinA - Viatris/Revance; OnabotulinumtoxinA - Viatris/Revance

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revance Therapeutics
  • Developer Revance Therapeutics; Viatris Inc
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral, Injection)
  • 28 May 2021 Revance Therapeutics and Viatris announces intention to submit IND to US FDA, in 2022
  • 25 Feb 2021 Preclinical trials in Unspecified in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top